ZA
LGND icon

Zazove Associates’s Ligand Pharmaceuticals LGND Stock Holding History

Zazove Associates’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-14,119
Closed -$1M – 129
2019
Q2 		$1M Buy
+14,119
New +$1.04M 0.09% 74
2019
Q1 		– Hold
0
– – – 66

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Zazove Associates's LGND Position: Q3 2019 in Review

Zazove Associates sold out of Ligand Pharmaceuticals (LGND) in Q3 2019, closing a stake of 14,119 shares — an estimated $1M sold.

Zazove Associates first reported a position in LGND in Q2 2019 and held it in 1 quarter. The position peaked at $1M in Q2 2019. 275 funds tracked by Wall St. Rank hold LGND as of Q3 2019.

  • Zazove Associates reported no remaining Ligand Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Zazove Associates sold 14,119 Ligand Pharmaceuticals shares in Q3 2019, an estimated $1M.
  • Zazove Associates first reported a position in Ligand Pharmaceuticals in Q2 2019 and held it in 1 quarter.
  • Zazove Associates's Ligand Pharmaceuticals position peaked at $1M in Q2 2019.
  • 275 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2019.

Based on Zazove Associates's 13F filing for Q3 2019, filed 28 Oct 2019.